Clinical and pathological characteristics of the 55 patients
| Characteristics | Number of patients (%) |
| Median age, years (IQR) | 69.1 (64.3–73.3) |
| Clinical NCCN risk group | |
| Low | 2 (3.6%) |
| Intermediate | 24 (43.6%) |
| High | 23 (41.8% |
| Pathologic T-category (pT) | |
| pT2 | 12 (21.8%) |
| pT3a | 13 (23.6%) |
| pT3b | 17 (30.9%) |
| Tx | 13 (23.6%) |
| Pathologic N-category (pN) | |
| pN0 | 27 (49.1%) |
| pN1 | 7 (12.7%) |
| pNx | 21 (38.2%) |
| Surgical margin status | |
| Negative | 25 (45.5%) |
| Positive | 30 (54.5%) |
| Pathologic Gleason score | |
| ≤ 6 | 4 (7.3%) |
| 7 | 26 (47.3%) |
| ≥ 8 | 16 (29.1%) |
| Unknown | 9 (16.3%) |
| ISUP grade group | |
| 1 | 1 (1.8%) |
| 2 | 10 (18.2%) |
| 3 | 19 (34.6%) |
| 4 | 4 (7.3%) |
| 5 | 12 (21.8%) |
| Unknown | 9 (16.3%) |
| Median interval between RadP
and BCR, mo (IQR) | 8.05 (1.9–33.8) |
| Median PSA prior to 68Ga
PSMA-PET/CT, ng/ml (IQR) | 2.19 (0.53–4.57) |
| < 0.5 | 13 |
| 0.5–1.0 | 8 |
| > 1.0–2.0 | 5 |
| > 2.0 | 28 |
| Missing | 1 |
| Median PSA doubling time, mo (IQR) | 11.6 (6.0–21.1) |
| Salvage Therapy | |
| RT alone | 6 (10.9%) |
| RT with HT | 20 (36.4%) |
| HT alone | 13 (23.6%) |
| Observation/Lost to follow up | 16 (29.1%) |
IQR: interquartile range, PSA: prostate specific antigen, R0: negative surgical margin, R1: positive surgical margin, ISUP: International society of urological pathology grading system for prostate cancer based on Gleason score, RadP: radical prostatectomy, BCR: biochemical relapse, RT: radiotherapy, HT: hormonal therapy.